To better understand how metabolomic dysregulation and genetic alterations are related to PCa, the main drivers of PCa oncogenic activity must be elucidated: AR expression, PTEN locus mutation, p53 locus mutation, and c-MYC amplification. This evidence concerns the gene PTEN and posterior cortical atrophy.